FY2025 EPS Estimates for Sanara MedTech Lowered by Analyst

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Sanara MedTech in a research report issued on Wednesday, March 26th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of ($2.43) for the year, down from their previous estimate of ($0.98). Cantor Fitzgerald currently has a "Overweight" rating and a $46.00 target price on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The business had revenue of $26.31 million for the quarter, compared to analysts' expectations of $22.75 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%.

Separately, HC Wainwright boosted their price target on Sanara MedTech from $50.00 to $51.00 and gave the company a "buy" rating in a research note on Wednesday, March 26th.

Sanara MedTech Price Performance

Shares of SMTI stock traded down $0.55 during mid-day trading on Friday, reaching $30.32. The company's stock had a trading volume of 7,066 shares, compared to its average volume of 23,161. Sanara MedTech has a 1-year low of $26.00 and a 1-year high of $39.08. The company has a market cap of $269.91 million, a P/E ratio of -30.69 and a beta of 1.37. The firm's 50-day moving average is $34.22 and its two-hundred day moving average is $33.72. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SMTI. State Street Corp lifted its position in shares of Sanara MedTech by 9.2% during the third quarter. State Street Corp now owns 58,688 shares of the company's stock worth $1,775,000 after purchasing an additional 4,932 shares in the last quarter. Barclays PLC raised its position in Sanara MedTech by 323.0% in the 3rd quarter. Barclays PLC now owns 5,731 shares of the company's stock worth $174,000 after purchasing an additional 4,376 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Sanara MedTech by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 88,271 shares of the company's stock worth $2,670,000 after buying an additional 3,755 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Sanara MedTech by 127.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company's stock valued at $123,000 after buying an additional 2,272 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new stake in shares of Sanara MedTech in the 4th quarter valued at $898,000. 8.10% of the stock is owned by institutional investors.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.